Shares of Opko Health Inc. (NYSE:OPK) ended Wednesday session in red amid volatile trading. The shares closed down -0.46 points or -4.43% at $9.92 with 3.84 million shares getting traded. Post opening the session at $10.29, the shares hit an intraday low of $9.91 and an intraday high of $10.35 and the price vacillated in this range throughout the day. The company has a market cap of $5.49 billion and the numbers of outstanding shares have been calculated to be 547.44 million shares.
Opko Health Inc. (OPK) on 11 May, 2016 announced the appointment of Douglass Laidlaw, PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE®.
Dr. Laidlaw has over 15 years of experience in leading strategic planning, development and execution of medical education initiatives for numerous pharmaceutical companies, including Relypsa, Keryx, Sanofi, Genzyme, Neurocine Biosciences, Serono and Organon. He has been involved in new product launches targeting patients with chronic kidney disease and has deep connections with key nephrology opinion leaders. Prior to joining OPKO, Dr. Laidlaw served as Relypsa’s Executive Director, Medical Affairs, and Sanofi’s National Director, Medical Science Liaisons, Medical Affairs.
“Doug is a key addition to the management team in OPKO’s Renal Division,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. “A well-conceived and executed medical education strategy is critical to Rayaldee’s acceptance by U.S. healthcare professionals.”
Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Wednesday session in red amid volatile trading. The shares closed down -0.14 points or -2.88% at $4.89 with 3.53 million shares getting traded. Post opening the session at $5.02, the shares hit an intraday low of $4.87 and an intraday high of $5.05 and the price vacillated in this range throughout the day. The company has a market cap of $1.14 billion and the numbers of outstanding shares have been calculated to be 228.74 million shares.
Exelixis, Inc. (EXEL) on May 4, 2016 reported financial results for the first quarter of 2016.
First Quarter 2016 Financial Results
Net revenues for the quarter ended March 31, 2016 were $15.4 million, compared to $9.4 million for the comparable period in 2015. Net revenues for the first quarter of 2016 consisted of $9.1 million of net product revenue related to the sale of COMETRIQ, $5.0 million of contract revenues for a milestone earned from Merck in the first quarter of 2016 related to their worldwide license of our PI3K-delta program and $1.2 million of license revenues recognized from the upfront payment we received from Ipsen under our collaboration and license agreement.
Research and development expenses for the quarter ended March 31, 2016 were $28.9 million, compared to $22.3 million for the comparable period in 2015. The increase was primarily related to an increase in stock-based compensation expense for performance-based stock-options and an annual bonus to our employees in the form of fully-vested restricted stock units, an increase in personnel related expenses resulting from an increase in headcount and an increase in consulting and outside services for medical affairs and drug safety.
Shares of Biocept Inc (NASDAQ:BIOC) ended Wednesday session in red amid volatile trading. The shares closed down -0.002 points or -0.30% at $0.827 with 344,201.00 shares getting traded. Post opening the session at $0.81, the shares hit an intraday low of $0.78 and an intraday high of $0.85 and the price vacillated in this range throughout the day. The company has a market cap of $20.18 million and the numbers of outstanding shares have been calculated to be 24.97 million shares.
Biocept Inc (BIOC) on May 5, 2016 announced that it will release financial results for the three months ended March 31, 2016 after market close on Thursday, May 12, 2016. Biocept management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
Individuals interested in participating on the conference call may do so by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4109 for other international callers. Those interested in listening to a webcast of the live conference call may do so by visiting http://ir.biocept.com/events.cfm.
A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering replay access code 10085489. A webcast replay will be available for 90 days at http://ir.biocept.com/events.cfm.